The major concern with my miracle drug, and others like it, is acquired resistance. Targeted therapies such as crizotinib work beautifully against cancers with the target mutations they are designed to exploit, but not forever. Eventually, the cancer mutates again, outsmarting the medicine.
I’m going to THIS next month, to hear from an all-star lineup of scientists, doctors, and patient advocates from the forefront of the research:
It’s also my first chance to meet other ROS1 patients face to face. I can’t wait.